News

A nanophotonics-based device implanted in the eye may one day enable patients with glaucoma to monitor their IOP from home.

As technology continues to advance, the ability to serve patients will greatly improve. Having sophisticated tools at our disposal will make medical decisions all the more appropriate and treatment plans all the more effective.

Using a new analytic approach to dig deeper into data from genome-wide association studies, researchers have found several common mechanisms underlying IOP.

Much work is being done with Adeno-associated virus (AAV) vectors for application in retinal gene therapy, with modifications being made to the capsid and genome of the vector to generate novel variants with unique transduction profiles, according to Shannon Boye, PhD.

The FDA has granted 510(k) clearance to Quantel Medical’s integrated laser platform, Optimis Fusion.

Zeiss has unveiled a new product-Zeiss Digital Lens-that targets the vision needs of the millennial generation. The company will also launch a consumer marketing approach designed to raise awareness and drive demand for the product.

Allergan is working on plans of its own to give investors "most of what they want" instead of the $53 billion hostile bid from Valeant Pharmaceuticals International and top Allergan shareholder Pershing Square, according to the company.

When consulting with patients who present with decreased vision due to cataracts, ophthalmologists need to remember their role as physicians first, suggest the authors. The primary goal of the office visit is to address the complaint and the solution in entirety before moving into outcomes.

Real-world experience with ocriplasmin (Jetrea, ThromboGenics) show that the treatment success rate can be increased by appropriate patient selection.

The widely used antidepressant bupropion appeared to protect against open-angle glaucoma in an analysis of a large health-care claims database.

Thanks to this research, I comprehend why some people insist they don’t find my columns to be particularly insightful or humorous. It’s not their fault. I blame myself. My writing is just too gosh-darned sophisticated.

The latest surveillance data on antibiotic resistance trends show increased levels of resistance among certain isolates, warranting ongoing, prospective, multicenter surveillance studies.

Despite the challenges of higher costs of developing drugs, increased regulatory requirements, and limitations on reimbursement for health care, the key to success in the pharmaceutical industry has been-and still is-innovation.

Ophthalmology has benefitted from many innovative new therapies in recent years. How do we continue to drive innovation? And how can we, as an industry, accelerate bringing new therapies to the marketplace?

Common imaging techniques-such as optical coherence tomography and ultrasound biomicroscopy-can be enlisted to help with research into retinal diseases when used to examine postmortem eyes, suggest findings from a collaborative research program.

Intravenous methylprednisolone may prevent visual loss and occasionally achieve visual recovery in patients with giant cell arteritis.

The open-label extension RIDE and RISE phase III studies of ranibizumab (Lucentis, Genentech) indicated that the beneficial results of the drug for treating diabetic macular edema were maintained over the long-term with less than monthly follow-up or injection treatment.

Maintaining both parents’ and children’s happiness when choosing pediatric eyewear requires a balancing act, supported by the physician and clinic staff.

The first results from a phase I trial of gene therapy for exudative age-related macular degeneration using a subretinal injection suggest that the treatment is safe and well tolerated even in the elderly population and may eliminate the need for frequent reinjection with anti-vascular endothelial growth factor agents.

The American Academy of Ophthalmology is reminding the public that it does not recommend marijuana or other cannabis products for the treatment of glaucoma.

A club drug and aphrodisiac since the 1970s, inhaled ‘poppers,’ have become increasingly linked to eye damage-perhaps due to a new formulation-according to a recent report from the United Kingdom.

A study designed to set an appropriate benchmark for LASIK is generating interesting findings in a preliminary analysis of outcomes at 1 year, said Francis Price Jr., MD.

The FDA has granted 510(k) clearance to Paragon BioTeck’s Comfortear Lacrisolve absorbable punctum plug.

Nicox S.A. has signed an agreement to acquire all of the outstanding equity of Aciex Therapeutics, a private, U.S.-based, ophthalmic development pharmaceutical company with a pipeline of therapeutics addressing the ophthalmic market, including allergy and inflammation.

Ohr Pharmaceutical has announced positive top-line interim results for its double-masked, placebo-controlled phase II clinical trial of Squalamine eye drops in patients with wet age-related macular degeneration (AMD).

Aerie Pharmaceuticals has reported successful results for a phase IIb trial for its IOP-lowering therapy-once-daily, quadruple-action Roclatan, a combination of Aerie’s triple-action Rhopressa with latanoprost.

Alimera Sciences' sustained-release intravitreal implant (Iluvien)-its treatment of chronic macular edema-has received a positive outcome of the Repeat-Use Procedure with the Medicines and Healthcare products Regulatory Agency of the United Kingdom serving as the Reference Member State.

To improve morale, managers need to have a pulse on the dynamics of the group and work on the issues that can cause daily frustration.